Bicyclic Modulators of Integrated Stress Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively modulate the integrated stress response (ISR) pathway, particularly in addressing diseases related to eIF2α phosphorylation and eIF2B activity, which are implicated in neurodegenerative, inflammatory, and metabolic disorders.
Innovation Solution
Development of compounds that modulate eIF2B activity, specifically activating eIF2B and attenuating the ISR signaling pathway, as represented by compounds of Formula (I) or their pharmaceutically acceptable salts, solvates, hydrates, tautomers, or stereoisomers, for use in treating neurodegenerative diseases, leukodystrophies, cancers, inflammatory diseases, and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated in response to stress signals, then cellular stress response is activated, but translation initiation is attenuated
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to bind to eIF2B and modulate its activity. These compounds act as mediators between the stress signal and the translation initiation process, allowing selective enhancement of eIF2B activity without directly interfering with eIF2α phosphorylation. The compounds stabilize the eIF2B dimer conformation and enhance its GEF activity, thereby restoring translation initiation while maintaining stress response signaling.
Solution Approach 2:
The patent changes the activity parameter of eIF2B by introducing small molecule compounds that enhance its guanine nucleotide exchange factor (GEF) activity. This parameter change allows the system to overcome the translation attenuation caused by eIF2α phosphorylation. The compounds specifically increase the rate of GDP/GTP exchange on eIF2, thereby restoring ternary complex formation and translation initiation without altering the phosphorylation status of eIF2α.
2Productivity
If eIF2B activity is enhanced to restore translation, then productivity increases, but the balance of ISR pathway may be disrupted
Solution Approach 1:
The patent applies partial action by selectively enhancing eIF2B activity rather than completely overriding the ISR pathway. The small molecule compounds provide a moderate enhancement of eIF2B GEF activity that is sufficient to restore translation initiation but does not completely abolish the stress response signaling. This partial action allows the system to regain productivity while maintaining the protective stress response at appropriate levels.
Solution Approach 2:
The patent uses small molecule compounds that copy or mimic the effect of ISRIB (integrated stress response inhibitor-binding compound) by stabilizing the eIF2B dimer conformation. These compounds replicate the beneficial effect of endogenous regulators that naturally modulate eIF2B activity, thereby restoring translation initiation in a manner that is consistent with physiological regulation and does not disrupt the overall ISR pathway balance.
3Reliability
If small molecule compounds are developed to modulate eIF2B, then therapeutic potential increases, but device complexity increases
Solution Approach 1:
The patent employs small molecule compounds that are chemically simple and can be synthesized through standard organic chemistry methods. These molecules are designed to be relatively simple in structure (e.g., containing common pharmacophores like heterocyclic rings, amide groups, and aromatic systems) rather than complex macromolecules. This approach allows for easier synthesis, purification, and potential cost-effective production, while still achieving the desired therapeutic effect of modulating eIF2B activity.
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.